Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach